DULLES, Va., Oct. 13, 2022 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [68 Ga]FAPI-46 ...
DULLES, Va., Feb. 11, 2026 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the ...
DULLES, Va., Nov. 29, 2022 /PRNewswire/ -- SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to ...
DULLES, Va., Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of ...
SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, announced that the first patient has been dosed in the second of its two phase 3 clinical trials evaluating 18F ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results